Products
Preparation registered in Ukraine
Abrahamovich O., Fainik A., Nechai O., Perepelitsa M., Sorokovskii M., Fainik O.
Efficacy and safety of nebivolol in treatment of patients with acute myocardial infarction
The aim of the study was to compare the effect of nebivolol and metoprolol on clinical and hemodynamic parameters in patients with Q myocardial infarction (MI) of anterior-lateral region of the left ventricle. The study included 56 men with acute first MI with the Q wave aged up to 65 years. Group 1 included patients with MI (n=28) who received metoprolol at a dose of 25–100 mg/day in two divided doses. Patients of Group 2 (n=28) received nebivolol (Nebival manufactured by “Kyiv Vitamin Factory”) at an average dose of 4,7±1,2 mg/day). The effect on hemodynamics, exercise tolerance, and antiarrhythmic effect of nebivolol is not inferior to metoprolol in patients with acute MI. In patients with acute MI and ejection fraction ≤40 the higher dose of nebivolol compared to an equivalent dose of metoprolol may be achieved, which determines better control for the average heart rate at night, as well as maximum heart rate in active and passive period in these patients. There is better tolerability of nebivolol compared to metoprolol in patients with acute MI.
Key words: acute myocardial infarction, nebivolol, metoprolol.